KPL-387
Recurrent Pericarditis
Phase 2/3Active, Recruiting (Study KPL-387-C211)
Key Facts
Indication
Recurrent Pericarditis
Phase
Phase 2/3
Status
Active, Recruiting (Study KPL-387-C211)
Company
About Kiniksa Pharmaceuticals
Founded in 2015 and publicly traded on NASDAQ, Kiniksa Pharmaceuticals is dedicated to advancing transformative therapies, with a core focus on cardiovascular diseases. Its key achievement is the 2021 FDA approval and commercial launch of ARCALYST for recurrent pericarditis, providing a critical treatment for a serious inflammatory heart condition. The company's strategy involves leveraging validated immune-modulating pathways, pursuing multiple indications for its assets, and forming strategic collaborations to expand its global reach and pipeline potential.
View full company profileTherapeutic Areas
Other Recurrent Pericarditis Drugs
| Drug | Company | Phase |
|---|---|---|
| ARCALYST (rilonacept) | Kiniksa Pharmaceuticals | Commercial |
| VTX2735 | Ventyx Biosciences | Phase 2 |